

Charakteristika predkladaného výstupu tvorivej činnosti / Characteristics of the submitted research/ artistic/other output

Tlačivo VTC slúži na predkladanie výstupov tvorivej činnosti podľa metodiky hodnotenia tvorivých činností (časť V. Metodiky na vyhodnocovanie štandardov) / The form is used to submit the research/artistic/other outputs according to the evaluation methodology of research/artistic/other activities (part V. The Methodology for Standards Evaluation).

ID konania/ID of the procedure: ¹	
Kód VTC/Code of the research/artistic/other output (RAOO): ¹	

OCA1. Priezvisko hodnotenej osoby / Surname awarded to the assessed person ²	Klimas
OCA2. Meno hodnotenej osoby / Name awarded to the assessed person ²	Ján
OCA3. Tituly hodnotenej osoby / Degrees awarded to the assessed person ²	prof., PharmDr., PhD., MPH.
OCA4. Hyperlink na záznam osoby v Registri zamestnancov vysokých škôl / Hyperlink to the entry of the person in the Register of university staff ³	https://www.portalys.sk/regzam/detail/3726
OCA5. Oblasť posudzovania / Area of assessment ⁴	Magisterský študijný program Farmácia / Master Degree Study Programme Pharmacy - Doktorandský študijný program Klinická farmácia/PhD.Study
OCA6. Kategória výstupu tvorivej činnosti / Category of the research/ artistic/other output <i>Výber zo 6 možností (pozri Vysvetlivky k položke OCA6) / Choice from 6 options (see Explanations for OCA6).</i>	vedecký výstup / scientific output
OCA7. Rok vydania výstupu tvorivej činnosti / Year of publication of the research/artistic/other output	2021
OCA8. ID záznamu v CREPČ alebo CREUČ (ak je) / ID of the record in the Central Registry of Publication Activity (CRPA) or the Central Registry of Artistic Activity (CRAA) ⁵	307263
OCA9. Hyperlink na záznam v CREPČ alebo CREUČ / Hyperlink to the record in CRPA or CRAA ⁶	https://app.crepc.sk/?fn=detailBiblioFormChildeKEN2&sid=D6D1207F88D43CD7265E0D809F&seo=CREP%C4%8C-detail-%C4%8C%C3%A1nok
bo CREUČ / Characteristics of the output that is not registered in CRPA or CRAA	OCA10. Hyperlink na záznam v inom verejne prístupnom registri, katalógu výstupov tvorivých činností / Hyperlink to the record in another publicly accessible register, catalogue of research/ artistic/other outputs ⁷
	https://www.scopus.com/record/display.uri?eid=2-s2.0-85104719031&origin=resultslist&sort=plf-f&featureToggles=FEATURE_NEW_DOC_DETAILS_EXPORT:1
	OCA11. Charakteristika výstupu vo formáte bibliografického záznamu CREPČ alebo CREUČ, ak výstup nie je vo verejne prístupnom registri alebo katalógu výstupov / Characteristics of the output in the format of the CRPA or the CRAA bibliographic record, if the output is not available in a publicly accessible register or catalogue of outputs
	N/A
	OCA12. Typ výstupu (ak nie je výstup registrovaný v CREPČ alebo CREUČ) / Type of the output (if the output is not registered in CRPA or CRAA) <i>Výber zo 67 možností (pozri Vysvetlivky k položke OCA12) / Choice from 67 options (see Explanations for OCA12).</i>
OCA13. Hyperlink na stránku, na ktorej je výstup sprístupnený (úplný text, iná dokumentácia a podobne) / Hyperlink to the webpage where the output is available (full text, other documentation, etc.)	https://www.liebertpub.com/doi/10.1089/gtmb.2020.0277?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_p ub++0pubmed
OCA14. Charakteristika autorského vkladu / Characteristics of the author's contribution	Stanovenie hypotézy a cieľov, návrh metód výskumu, príprava rukopisu / Determination of hypothesis and aims, design of research methods, preparation of manuscript

Charakteristika výstupu, ktorý nie je registrovaný v CREPČ ale	OCA15. Anotácia výstupu s kontextovými informáciami týkajúcimi sa opisu tvorivého procesu a obsahu tvorivej činnosti a pod. / Annotation of the output with contextual information concerning the description of creative process and the content of the research/artistic/other activity, etc. ⁸ <i>Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in Slovak</i> <i>Rozsah do 200 slov v anglickom jazyku / Range up to 200 words in English</i>	MikroRNA, malé nekódujúce molekuly RNA regulujúce génovú expresiu na post-transkripčnej úrovni, sú silnými modulátormi srdcovej remodelácie pri srdcovom zlyhaní (SZ). Viaceré cirkulujúce miRNA boli popísané ako kandidátske diagnostické biomarkery; medzi nimi bola miR-21 označená ako najlepší kandidát pre SZ. Cieľom tejto štúdie bolo študovať vzťah medzi sérovými koncentraciami miR-21 a anémiou u pacientov trpiacich SZ s redukovanou ejekčnou frakciou (SZrEF). Použili sme klinické a experimentálne diagnostické nástroje a analyzovali sme farmakoterapiu. Naše zistenia naznačujú, že hladiny miR-21 odzrkadľujú skôr iné charakteristiky pacientov s SZrEF ako štandardné identifikátory závažnosti a progresie SZ. / MicroRNAs, small noncoding RNA molecules regulating gene expression at the post-transcriptional level, are potent modulators of cardiac remodeling in heart failure (HF). Multiple circulating miRNAs have been described as candidates for diagnostic biomarkers; among them, miR-21 has been suggested as a top candidate when studying HF. The aim of this study was to study the relationship between serum miR-21 concentrations and anemia in patients suffering from HF with reduced ejection fraction (HFrEF). We used clinical and experimental diagnostic tools and analyzed the pharmacotherapy. Our findings suggest that miR-21 levels mirror other characteristics of patients with HFrEF rather than standard identifiers of HF severity and progression.
---	---	---

OCA16. Anotácia výstupu v anglickom jazyku / Annotation of the output in English ⁹ <i>Rozsah do 200 slov / Range up to 200 words</i>	Aim: Circulating microRNA-21 (miR-21) has been utilized as a diagnostic tool in the assessment of heart failure (HF). Blood constitution may be altered when HF occurs and miR-21 may affect hematopoiesis. Sample hemolysis may influence the determination of circulating miRNAs, challenging the diagnostic use of miRNAs. Methods: We examined the relationship between blood measurements and miR-21 levels in ambulant chronic HF patients with reduced ejection fraction (HFrEF; n = 19). Healthy volunteers (n = 11) served as controls. Serum miR-21 levels were measured through quantitative reverse transcription polymerase chain reaction (RT-qPCR) and we calculated the hemolysis score (H-score). The study was approved by our Institutional Review Board (EK FaF UK 02/2018). Results: MiR-21 serum levels were reduced in HFrEF patients compared with the controls (p < 0.05), without relationship to New York Heart Association class, left ventricular ejection fraction, or N-terminal prohormone of brain natriuretic peptide levels. MiR-21 levels decreased markedly in anemic patients, compared with those with normal hematocrits (p < 0.05). We found a significant relationship between miR-21 to hematocrit (p < 0.05) and hemoglobin concentration (p < 0.05). Importantly, we found a correlation between hematocrit and sample H-score (p < 0.05) in the cohort of HFrEF patients; however, there was no correlation between hemolysis and miR-21. Conclusion: Circulating miR-21 levels were decreased in HFrEF patients and hematocrit was identified as a factor associated with this abnormality. This suggests that miR-21 mirrors other characteristics of HFrEF patients rather than the standard identifiers of HF severity and progression.
OCA17. Zoznam najviac 5 najvýznamnejších ohlasov na výstup / List of maximum 5 most significant citations corresponding to the output <i>Rozsah do 200 slov / Range up to 200 words</i>	[o1] 2021 Zhang, S., Sun, J., Gu, M., Wang, G., Wang, X. Circular RNA: A promising new star for the diagnosis and treatment of colorectal cancer; Cancer Medicine 10(24), pp. 8725-8740 - SCOPUS
OCA18. Charakteristika dopadu výstupu na spoločensko-hospodársku prax / Characteristics of the output's impact on socio-economic practice <i>Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in Slovak</i> <i>Rozsah do 200 slov v anglickom jazyku / Range up to 200 words in English</i>	V publikácii popisujeme úlohu a možnosti stanovenia cirkulujúcej microRNA-21 u pacientov liečených na zlyhávanie srdca, z čoho je možné čerpať pri výskume nových molekúl na liečbu zlyhávania srdca. / In this publication, we describe the role and possibilities of determining of circulating microRNA-21 in patients treated for heart failure, what can be used in the research of new molecules for the treatment of heart failure.
OCA19. Charakteristika dopadu výstupu a súvisiacich aktivít na vzdelávací proces / Characteristics of the output and related activities' impact on the educational process <i>Rozsah do 200 slov v slovenskom jazyku / Range up to 200 words in Slovak</i> <i>Rozsah do 200 slov v anglickom jazyku / Range up to 200 words in English</i>	Zistené výsledky môžu byť prezentované v rámci prednášok z farmakológie a klinickej farmakológie a klinickej farmácie v rámci predstavenia experimentálnych postupov výskumu a vývoja liečiv na kardiovaskulárne ochorenia. /The results can be presented in lectures of pharmacology and clinical pharmacology as a part of the presentation of experimental drug research for cardiovascular disorders.